Syce, James A.Bepe, Nyashadzashe2018-06-272024-05-152018-08-312024-05-152017https://hdl.handle.net/10566/15162Magister Pharmaceuticae - MpharmDissolution studies on various dosage forms (powder, tablets, teabags and alginate beads) of the Artemisia afra freeze dried aqueous extract (FDAE) all exhibit a rapid release profile. Generally, such a release profile may be therapeutically undesirable as it may affect absorption and hence the therapeutic outcome. In addition, also associated with rapid release profiles, is frequent dosing required (to maintain therapeutic plasma concentrations) and unavoidable fluctuations in plasma drug concentrations, leading to under and or over dosing. Based on the aforementioned shortcomings, there may be need to modify the dissolution profile of the phytoconstituents of A. afra. Phytosomes, which are complexes of phospholipids with phytoconstituents, offer a very viable dosage form option for A. afra as they could afford advantages of increased lipophilicity hence a decreased dissolution rate and improved absorption or permeability of the phytoconstituents.enUniversity of the Western Cape